SYnAbs and Volition ink strategic deal on epigenetic modifications targeting -- MEDICA - World Forum for Medicine

24/09/2020

SYnAbs S.A.

SYnAbs and Volition ink strategic deal on epigenetic modifications targeting

SYnabs will develop monoclonal antibodies of mice, rats, and guinea pigs against 16 different post-translational modifications on histones including methylation, acetylation, phosphorylation, and mutations.

Exhibitor Data Sheet